Show simple item record

AuthorSeidel, Alinadc.contributor.author
AuthorZanoni, Michelledc.contributor.author
AuthorGroß, Rüdigerdc.contributor.author
AuthorKrnavek, Danieladc.contributor.author
AuthorErdemci-Evin, Sümeyyedc.contributor.author
Authorvon Maltitz, Pascaldc.contributor.author
AuthorAlbers, Dan P. J.dc.contributor.author
AuthorConzelmann, Carinadc.contributor.author
AuthorLiu, Sichendc.contributor.author
AuthorWeil, Tatjanadc.contributor.author
AuthorMayer, Benjamindc.contributor.author
AuthorHoffmann, Markusdc.contributor.author
AuthorPöhlmann, Stefandc.contributor.author
AuthorBeil, Alexandradc.contributor.author
AuthorKroschel, Jorisdc.contributor.author
AuthorKirchhoff, Frankdc.contributor.author
AuthorMünch, Jandc.contributor.author
AuthorMüller, Janis A.dc.contributor.author
Date of accession2022-09-26T07:24:05Zdc.date.accessioned
Available in OPARU since2022-09-26T07:24:05Zdc.date.available
Date of first publication2022-07-25dc.date.issued
AbstractIn light of the decreasing immune protection against symptomatic SARS-CoV-2 infection after initial vaccinations and the now dominant immune-evasive Omicron variants, ‘booster’ vaccinations are regularly performed to restore immune responses. Many individuals have received a primary heterologous prime-boost vaccination with long intervals between vaccinations, but the resulting long-term immunity and the effects of a subsequent ‘booster’, particularly against Omicron BA.1, have not been defined. We followed a cohort of 23 young adults, who received a primary heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, over a 7-month period and analysed how they responded to a BNT162b2 ‘booster’. We show that already after the primary heterologous vaccination, neutralization titers against Omicron BA.1 are recognizable but that humoral and cellular immunity wanes over the course of half a year. Residual responsive memory T cells recognized spike epitopes of the early SARS-CoV-2 B.1 strain as well as the Delta and BA.1 variants of concern (VOCs). However, the remaining antibody titers hardly neutralized these VOCs. The ‘booster’ vaccination was well tolerated and elicited both high antibody titers and increased memory T cell responses against SARS-CoV-2 including BA.1. Strikingly, in this young heterologously vaccinated cohort the neutralizing activity after the ‘booster’ was almost as potent against BA.1 as against the early B.1 strain. Our results suggest that a ‘booster’ after heterologous vaccination results in effective immune maturation and potent protection against the Omicron BA.1 variant in young adults.dc.description.abstract
Languageendc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseCC BY 4.0 Internationaldc.rights
Link to license texthttps://creativecommons.org/licenses/by/4.0/dc.rights.uri
Keyworddeltadc.subject
KeywordB.1.1.529.1dc.subject
KeywordBA.1dc.subject
Keywordhumoral immunitydc.subject
KeywordChadOx1 nCoV-19dc.subject
Keywordvaccination intervaldc.subject
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
MeSHCOVID-19 vaccinesdc.subject.mesh
MeSHImmunity, Humoraldc.subject.mesh
MeSHMemory T cellsdc.subject.mesh
MeSHVaccine efficacydc.subject.mesh
TitleBNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adultsdc.title
Resource typeWissenschaftlicher Artikeldc.type
SWORD Date2022-08-08T06:42:16Zdc.date.updated
VersionpublishedVersiondc.description.version
DOIhttp://dx.doi.org/10.18725/OPARU-44792dc.identifier.doi
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-oparu-44868-8dc.identifier.urn
GNDCOVID-19dc.subject.gnd
GNDImpfungdc.subject.gnd
GNDGedächtniszelledc.subject.gnd
GNDHumorale Immunitätdc.subject.gnd
FacultyMedizinische Fakultätuulm.affiliationGeneral
InstitutionUKU. Institut für Molekulare Virologieuulm.affiliationSpecific
InstitutionInstitut für Epidemiologie und Medizinische Biometrieuulm.affiliationSpecific
InstitutionUKU. Zentrale Einrichtung Klinische Chemie (ZEKCh)uulm.affiliationSpecific
InstitutionKompetenzzentrum "Ulm Peptide Pharmaceuticals (U-PEP)"uulm.affiliationSpecific
Peer reviewjauulm.peerReview
DCMI TypeTextuulm.typeDCMI
CategoryPublikationenuulm.category
DOI of original publication10.3389/fimmu.2022.882918dc.relation1.doi
Source - Title of sourceFrontiers in Immunologysource.title
Source - Place of publicationFrontiers Mediasource.publisher
Source - Volume13source.volume
Source - Year2022source.year
Source - Article number882918source.articleNumber
Source - eISSN1664-3224source.identifier.eissn
EU project uulmFight-nCoV / FIGHTING-OFF CORONAVIRUS (SARS-CoV-2) WITH BROAD-SPECTRUM ANTIVIRALS: ESTABLISHING ANIMAL VIRAL CHALLENGE MODEL / EC / H2020 / 101003555uulm.projectEU
Open AccessGreen Published, golduulm.OA
WoS000838064300001uulm.identifier.wos
Bibliographyuulmuulm.bibliographie
Is Supplemented Byhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.882918/full#supplementary-materialdc.relation.isSupplementedBy
DFG project uulmSFB 1279 / Nutzung des menschlichen Peptidoms für die Entwicklung neuer antimikrobieller und anti-Krebs Therapeutika / DFG / 316249678uulm.projectDFG
DFG project uulmSARS-CoV-2 induzierte Schädigung des Alveolarepithels und dessen Inhibition durch α1-antitrypsin / DFG / 458685747 [MU 3115/13-1]uulm.projectDFG
DFG project uulmEndokrine In-vitro-Modelle zur Untersuchung der Pathophysiologie und Diabetes bei SARS-CoV-2 - COVID-19 / DFG / 458701159 [MU 3115/14-1]uulm.projectDFG
xmlui.metadata.uulm.OAfundingOpen-Access-Förderung durch die Medizinische Fakultät der Universität Ulmuulm.OAfunding


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record